Michael D. Cannon

CIK: 0001203602

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

MBRX

Moleculin Biotech, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (2 total)

MBRX
Moleculin Biotech, Inc.
Nov 12, 2025
Award(A)
Stock Options (right to buy)
Direct
150K shares-
MBRX
Moleculin Biotech, Inc.
Nov 4, 2024
Award(A)
Stock option (right to buy)
Direct
10K shares-

		Type	Shares	Price		Ownership
Nov 12, 2025	MBRX Moleculin Biotech, Inc.	Award(A) Stock Options (right to buy)	150,000	-	-	Direct
Nov 4, 2024	MBRX Moleculin Biotech, Inc.	Award(A) Stock option (right to buy)	10,000	-	-	Direct

1-2 of 2 transactions

About CANNON MICHAEL D

CANNON MICHAEL D (SEC CIK 0001203602) files insider reports with the SEC as Director of Moleculin Biotech, Inc. (MBRX).

Signal8 holds 2 ownership filings by CANNON MICHAEL D, all Form 4s, filed between Nov 6, 2024 and Nov 14, 2025. Those filings report 2 transactions, from Nov 4, 2024 to Nov 12, 2025. Signal8's Form 4 history starts in Sep 2024.

The business address on CANNON MICHAEL D's filings is in HOUSTON, TX.

Recent filings by CANNON MICHAEL D

Nov 12, 2025: Grant or award of MBRX derivative securities (Form 4, code A).
Nov 4, 2024: Grant or award of MBRX derivative securities (Form 4, code A).

Other insiders filing for Moleculin Biotech, Inc. (MBRX)

PICKER DONALD H, Chief Science Officer
KLEMP WALTER V, CEO and President
Foster Jonathan P., Chief Financial Officer
Yan Joy, Director
Cermak Elizabeth, Director
Climaco John M, Director

How to read Form 4 transaction codes